Brief: Peptidream Announces Collaboration, License Agreement With MSD For Novel Peptide Drug Conjugates
27/12/2022 13:10
Dec 27 (Reuters) - PeptiDream Inc 4587.T :
* PEPTIDREAM ANNOUNCES COLLABORATION AND LICENSE AGREEMENT
WITH
MSD FOR THE DISCOVERY AND DEVELOPMENT OF NOVEL PEPTIDE DRUG
CONJUGATES
* PEPTIDREAM - CO WILL BE ELIGIBLE FOR PAYMENTS BASED ON
ACHIEVEMENT OF SPECIFIED DEVELOPMENT, REGULATORY, & MILESTONES
POTENTIALLY TOTALING UP TO $2.1 BILLION
* PEPTIDREAM INC - UNDER TERMS OF AGREEMENT, PEPTIDREAM WILL
RECEIVE AN UPFRONT PAYMENT FROM MSD
Source text for Eikon: ID:nBw6YzP7Wa
Further company coverage: 4587.T
((reuters.briefs@thomsonreuters.com;))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner